These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
487 related articles for article (PubMed ID: 12827536)
1. Voriconazole in the treatment of invasive mold infections in transplant recipients. Fortún J; Martín-Dávila P; Sánchez MA; Pintado V; Alvarez ME; Sánchez-Sousa A; Moreno S Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):408-13. PubMed ID: 12827536 [TBL] [Abstract][Full Text] [Related]
2. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215 [TBL] [Abstract][Full Text] [Related]
3. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. Espinel-Ingroff A J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain]. Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM; Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811 [TBL] [Abstract][Full Text] [Related]
6. Voriconazole : a review of its use in the management of invasive fungal infections. Scott LJ; Simpson D Drugs; 2007; 67(2):269-98. PubMed ID: 17284090 [TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101 [TBL] [Abstract][Full Text] [Related]
8. [Isolation of Scedosporium apiospermum (teleomorph: Pseudallescheria apiosperma) from an acute myeloid leukemia patient]. Ergin C; Kutlu M; Arıkan Akdağlı S; Sarıbaş Z; Aydeniz Ozansoy F; Sarı I; Dursunoğlu N Mikrobiyol Bul; 2013 Apr; 47(2):351-5. PubMed ID: 23621736 [TBL] [Abstract][Full Text] [Related]
9. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539 [TBL] [Abstract][Full Text] [Related]
10. Activity of voriconazole against corneal isolates of Scedosporium apiospermum. Shah KB; Wu TG; Wilhelmus KR; Jones DB Cornea; 2003 Jan; 22(1):33-6. PubMed ID: 12502945 [TBL] [Abstract][Full Text] [Related]
11. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Bhatti Z; Shaukat A; Almyroudis NG; Segal BH Mycopathologia; 2006 Jul; 162(1):1-15. PubMed ID: 16830186 [TBL] [Abstract][Full Text] [Related]
12. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed. Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210 [TBL] [Abstract][Full Text] [Related]
13. [The role of voriconazole in the treatment of emerging mycoses]. Pastor FJ; Guarro J Rev Iberoam Micol; 2007 Sep; 24(3):228-32. PubMed ID: 17874861 [TBL] [Abstract][Full Text] [Related]
14. Review of the safety and efficacy of voriconazole. Hoffman HL; Rathbun RC Expert Opin Investig Drugs; 2002 Mar; 11(3):409-29. PubMed ID: 11866669 [TBL] [Abstract][Full Text] [Related]
15. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Johnson LS; Shields RK; Clancy CJ Transpl Infect Dis; 2014 Aug; 16(4):578-87. PubMed ID: 24962102 [TBL] [Abstract][Full Text] [Related]
16. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Radford SA; Johnson EM; Warnock DW Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501 [TBL] [Abstract][Full Text] [Related]
17. Voriconazole -- better chances for patients with invasive mycoses. Ghannoum MA; Kuhn DM Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915 [TBL] [Abstract][Full Text] [Related]
18. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Cecil JA; Wenzel RP Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966 [TBL] [Abstract][Full Text] [Related]
19. Voriconazole: a new triazole antifungal agent. Johnson LB; Kauffman CA Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645 [TBL] [Abstract][Full Text] [Related]
20. Voriconazole: in the treatment of invasive aspergillosis. Muijsers RB; Goa KL; Scott LJ Drugs; 2002; 62(18):2655-64; discussion 2665-6. PubMed ID: 12466006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]